This HTML5 document contains 135 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
n11http://dx.doi.org/10.1158/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q45917429
rdf:type
wikibase:Item
schema:description
wetenschappelijk artikel vetenskaplig artikel 2009年學術文章 vědecký článek наукова стаття, опублікована в липні 2009 ২৮ জুলাই ২০০৯-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ 2009年学术文章 artikulong pang-agham artigo científico scientific article published on 28 July 2009 vitskapeleg artikkel 2009년 논문 articolo scientifico מאמר מדעי επιστημονικό άρθρο article scientifique научная статья artículo científico publicado en 2009 tudományos cikk 2009年學術文章 บทความทางวิทยาศาสตร์ 2009年學術文章 мақолаи илмӣ 2009年学术文章 bài báo khoa học 2009 nî lūn-bûn 2009年学术文章 artikull shkencor 2009年学术文章 teaduslik artikkel tieteellinen artikkeli artigo científico scientific article published on 28 July 2009 научни чланак научни чланак artykuł naukowy naučni članak artículu científicu научна статия articol științific مقالة علمية نشرت في 28 يوليو 2009 სამეცნიერო სტატია 2009年学术文章 2009年の論文 2009年學術文章 2009年学术文章 videnskabelig artikel vedecký článok artigo científico scientific article published on 28 July 2009 article scientific artikel ilmiah vitenskapelig artikkel article científic scienca artikolo 2009年學術文章 bilimsel makale wissenschaftlicher Artikel
p:P577
wds:Q45917429-239BF3A8-A3AE-488E-88B6-A3ADBD44F8CA
wdt:P577
2009-07-28T00:00:00Z
p:P407
wds:Q45917429-9E9747A2-2A94-4BC7-83CB-C4E1BCB26C23
wdt:P407
wd:Q1860
p:P2093
wds:Q45917429-E1A48F41-6226-4927-B79B-F02E83D85148 wds:Q45917429-F94881A5-C877-4FA2-810C-0CCE59A7A517 wds:Q45917429-FEBAE672-1BC6-4D41-9389-8B393F991CA9 wds:Q45917429-294146D4-E6F6-4353-B762-A02DA7603794 wds:Q45917429-BF99BC21-1A4B-4425-BEB4-668516916B6A wds:Q45917429-B0126D1E-F666-4944-8E04-E0B5F0520E8C wds:Q45917429-84CE3424-83F3-4041-8EC1-3B7609AA3586 wds:Q45917429-79379D9D-FE00-4492-96AF-DAC0FE480226
wdt:P2093
Carlo Finelli Lorenza Borin Anna Di Tucci Enrico Pogliani Vincenzo Liso Marco Gobbi Giuliana Alimena Giuseppe Fioritoni
rdfs:label
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.
skos:prefLabel
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.
schema:name
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.
p:P50
wds:Q45917429-034A9633-1332-45EC-8EF4-1C3410017208 wds:Q45917429-0D5E9472-1E61-4890-A8EE-FE2DBBBDF3E6 wds:Q45917429-28917596-881A-41C1-A4D4-177BDD46F0AA wds:Q45917429-3CCE8893-4F8E-4C50-8413-221893ACFA66 wds:Q45917429-4355ABAF-1893-4D39-955A-086A4C4D0BE3 wds:Q45917429-4804CD33-AA9A-4EE5-AE77-A2BCA6795EB5 wds:Q45917429-4989DBF4-3AA3-456F-B7B0-9C4012868B7B wds:Q45917429-549396F2-1578-4AF2-AFC0-56675824994A wds:Q45917429-668E2B90-9E59-438F-AB3B-A6EE7231C9E1 wds:Q45917429-7080D72F-CF8C-4564-B506-819E8513FCA2 wds:Q45917429-7485673D-494F-4355-B333-2D65D3C87914 wds:Q45917429-977E8F30-75B3-4C88-8E19-D904151B781C wds:Q45917429-9D76248B-5346-44F6-8EF4-09A79E48045C wds:Q45917429-A4DCFBAC-A026-4DCF-B6A8-8DA005162FC6 wds:Q45917429-A7A9E125-2BD2-4BC4-8CFD-C5DA21CFD45D wds:Q45917429-D92A35D9-25F3-4A4C-A2F1-AB066CE2236D
wdt:P50
wd:Q57053558 wd:Q91676553 wd:Q56724874 wd:Q56850341 wd:Q57553823 wd:Q56461136 wd:Q90955283 wd:Q41237865 wd:Q38322944 wd:Q64171936 wd:Q87725588 wd:Q37841576 wd:Q117237094 wd:Q91833063 wd:Q37834492 wd:Q114575433
p:P1476
wds:Q45917429-6E3445DD-2CC8-4570-A566-59BDD4D5FF10
wdt:P1476
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes
p:P304
wds:Q45917429-4629041B-37BA-4602-8A8C-15871778883A
wdt:P304
5002-5007
p:P31
wds:Q45917429-169DD01B-D954-4031-B0A0-6D5B4E0C648B
wdt:P31
wd:Q13442814
p:P698
wds:Q45917429-C842F33F-F444-40BB-8239-441C0CA5A65E
wdtn:P698
n8:19638460
wdt:P698
19638460
p:P1433
wds:Q45917429-B72CDC5A-3695-4F82-B6D8-42E51BD3B552
wdt:P1433
wd:Q332253
p:P433
wds:Q45917429-63358A4F-81A4-45EA-9DDE-24420B2133C1
p:P478
wds:Q45917429-E0E9A48B-B092-433B-8F30-7BF27BAB85EC
wdt:P433
15
wdt:P478
15
p:P356
wds:Q45917429-481E46B8-CBF8-4900-BD2D-A0A2DD4743BB
wdtn:P356
n11:1078-0432.CCR-09-0494
wdt:P356
10.1158/1078-0432.CCR-09-0494